A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Authors
Rodon
J
Jordi
,
Tawbi
HA
Hussein A
,
Thomas
AL
Anne L
,
Stoller
RG
Ronald G
,
Turtschi
CP
Christian P
,
Baselga
J
Jose
,
Sarantopoulos
J
John
,
Mahalingam
D
Devalingam
,
Shou
Y
Yaping
,
Moles
MA
Melissa A
,
Yang
L
Lin
,
Granvil
C
Camille
,
Hurh
E
Eunju
,
Rose
KL
Kristine L
,
Amakye
DD
Dereck D
,
Dummer
R
Reinhard
,
Mita
AC
Alain C
.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 4 1; 20(7).
1900-9
Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 4 1; 20(7).
1900-9
Abstract
This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.
This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.